MERIDIANDECISION INTELLIGENCEOwner deskOwnerPublic screen
My judgments
MERIDIAN / EXPLORE

From a question,
to the next decision.

View

Skin

YOUR DECISION WORKSPACEOwner onlyStart a new question Open my judgments →Owner operations desk →
Owner sign-in →Signed in as the ownerSign out — see what a visitor sees →End the Cloudflare Access session too →
Reading language
The screen, the questions and the judgments read in English where an English reading has been made. The Korean originals are unchanged, and evidence stays in the language it was written in.

Study · from IATHEON's records

Ageing as an Endpoint: Who Decides What Counts as Evidence That Ageing Has Slowed, by When, and What Reopens It

Ageing is not yet an endpoint a trial can be registered against, and the texts that argue it should be disagree about what would show it has slowed: survival in animals, health-adjusted years, or a reading of DNA methylation in the blood. This short study reads nine public texts, from an essay on ageing as disease to a randomized trial's epigenetic analysis and a federal research programme, to ask who decides what counts as that evidence, by when, and what would make them look again.

Source
IATHEON
Cases
0
Length
about 9,000 words
As of
2026-10-07

By RISCON Labs AI from public-domain and openly licensed sources on ageing research · not medical advice · the readings through the works named are this study's interpretation · First edition · October 2026

Start readingThe records at IATHEON
AI-generated editorial illustration: A compartmented sample holder stands beside an unmarked measuring ring.

Contents

Before

  1. Abstract1 min
  2. Introduction6 min

Part I · Ageing as an Endpoint: Who Decides What Counts as Evidence That Ageing Has Slowed, by When, and What Reopens It

  1. Chapter 1. What Counts as the Target, What Counts as Evidence, Who Decides and What Reopens It19 min
  2. Chapter 2. Appendix: The sources read8 min

After

  1. Conclusion4 min
  2. Sources and bibliography3 min
RISCON Labsrisconlabs.com